Molecular Targets and Cancer Therapeutics:
Discovery, Biology, and Clinical Applications
November 15-19, 2009
Hynes Convention Center
Boston, Massachusetts
View Program
Download Call for Abstracts
Abstract submission and early registration deadline:
Thursday, September 10
Housing deadline:
Friday, October 9
ORGANIZING COMMITTEE:
Raymond N. DuBois, UT M.D. Anderson Cancer Center, Houston, TX, USA (AACR)
Anna D. Barker, National Cancer Institute, Bethesda, MD, USA (NCI)
Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium (EORTC)
SCIENTIFIC COMMITTEE CHAIRPERSONS:
Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA, USA (AACR)
James H. Doroshow, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA (NCI)
Ahmad Awada, Institut Jules Bordet, Brussels, Belgium (EORTC)
This conference, hosted by AACR, NCI and EORTC, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology. Understanding the pathways and mechanisms which cause cancer and regulate the biological behavior of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. This conference has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development. It will bring together delegates from all over the world igniting a huge exchange of information and promoting and developing global partnerships in translational research.
The American Association for Cancer Research (AACR), is a nonprofit scientific society of nearly 29,000 laboratory, translational, and clinical cancer researchers whose mission is to prevent and cure cancer through research, education, and communication.
The National Cancer Institute (NCI), founded in 1971, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.
The European Organization for Research and Treatment of Cancer (EORTC), is an international non-profit research organization created in 1962. The mission of the EORTC is to conduct, develop, coordinate and stimulate translational and clinical research in Europe, and to improve the management of cancer and related problems by increasing the survival and quality of life for patients.